Article
07 Jul 2026
FDA Advisory Committee Votes In Favor Of Moderna Flu Vaccine Benefit-Risk Profile
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in United States
AUTHORS CONTENT
Article
15 Apr 2026
FDA Approves First Gene Therapy For Rare Pediatric Immune Disorder Severe Leukocyte Adhesion Deficiency Type I
Article
14 Apr 2026
FDA Approves Extended Dosing Interval For Regeneron’s EYLEA HD (Aflibercept)
Article
22 Jan 2026
Year In Review: Top Legal Developments Of 2025
Article
28 Nov 2025
Formycon Announces New Dupilumab Biosimilar Candidate
Article
30 Sep 2025
Factor Bioscience Sues Cellectis And AstraZeneca Alleging Infringement Of Gene-Editing Patents
Article
20 Aug 2025
European Commission Approves Moderna's Updated COVID-19 Vaccine
Article
04 Jun 2025
EMA Issues Positive CHMP Opinions For Fresenius Denosumab Biosimilars
Article
05 May 2025
EmblemHealth Files Class Action Antitrust Against Alexion Related To Eculizumab
Article
20 Feb 2025
UK's MHRA Grants Marketing Authorization For Chikungunya Vaccine
Article
06 Jan 2025
EMA's CHMP Recommends Approval Of Six New Biosimilars
Article
20 Nov 2024
FDA Approves CAR-T Cell Therapy For Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
Article
16 Oct 2024
Amgen Files BPCIA Complaint Against Fresenius Kabi Regarding Denosumab
Article
10 Sep 2024
The Centers For Medicare & Medicaid Services Announces Lower Prices For First Ten Drugs Selected For Medicare Price Negotiation
Article
05 Aug 2024
FDA Issues Draft Guidance On Postapproval Manufacturing Changes To Biosimilar Products
Article
01 Jul 2024
Eculizumab BPCIA Litigation Update: Court Denies Alexion's Motion For An Injunction Pending Appeal
Article
25 Apr 2024
Fresenius Kabi Announces Launch Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA
Article
19 Mar 2024
Fresenius Kabi Announces FDA Approval Of TYENNE, A Tocilizumab Biosimilar Referencing ACTEMRA
Article
11 Jan 2024
Regeneron's Disputes With Celltrion, Samsung Bioepis, And Formcycon On Service And Personal Jurisdiction In Aflibercept BPCIA Litigation
Article
31 Oct 2023
Celltrion Announces FDA Approval Of ZYMFENTRA (Infliximab-dyyb)